Description
Varnismart (Varenicline) 1 mg
Varnismart 1 mg is a varenicline-containing medicine used as an aid to smoking cessation in adults. Varenicline is a prescription medicine and should be understood as part of a broader quit-smoking approach that may include behavioural support.
Active Ingredient and Medicine Class
The verified active ingredient is varenicline. It is a nicotinic acetylcholine receptor partial agonist, with activity at the α4β2 receptor subtype. This class is used to reduce nicotine dependence and support smoking cessation.
Established Medical Uses
Regulatory sources describe varenicline as indicated for smoking cessation in adults. Its approved use is to help people stop smoking, not to treat other conditions.
How It Works
Varenicline partly stimulates nicotine receptors while also blocking nicotine from binding fully to them. In practical terms, this can help lessen craving and withdrawal symptoms and reduce the rewarding effects of smoking.
Important Safety Information
Varenicline should not be used in people with a known hypersensitivity to the active substance or excipients. Product information also notes important precautions for neuropsychiatric symptoms, including changes in behaviour, mood, anxiety, aggression, depression, suicidal thoughts or behaviour, which have been reported in post-marketing use. Smoking cessation itself can change the handling of some medicines, including examples such as theophylline, warfarin and insulin.
Clinically relevant interaction information is limited, and one UK SmPC states that varenicline has no clinically meaningful drug interactions, while also noting limited data for alcohol-related effects.
Possible Side Effects
Commonly reported adverse effects include nausea, insomnia, abnormal dreams, headache, and nasopharyngitis. Other reported effects include sleep disturbance, appetite changes, weight increase, vomiting, dizziness and gastrointestinal discomfort. Serious or clinically important reactions can include mood or behaviour changes, suicidal ideation, and rare severe skin reactions.
Scientific Evidence
Peer-reviewed reviews and meta-analyses have found varenicline to be more effective than placebo for smoking cessation, with improved abstinence rates in clinical studies. Evidence also supports its role as an effective cessation aid, although nausea and sleep-related adverse effects are common.
Medical Information Notice
This summary is an educational overview based on sources available at the time of review. It does not replace the official patient leaflet, product information, or assessment by a qualified healthcare professional.
Medical Sources
- European Medicines Agency (EMA): Champix (varenicline) EPAR
- medicines.org.uk: Varenicline 1 mg film-coated tablets SmPC
- Shang X, et al. “Effectiveness and Safety of Varenicline for Smoking Cessation: An Overview and Meta-analysis.” J Addict Med. 2023. PubMed